에 대한 최신 뉴스 Merck & Co (NYSE:MRK) 주식

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

News

Politics

Markets

PHBBF

WUXAY

WXXWY

도널드 트럼프 대통령은 제약 회사들에게 제조를 미국으로 되돌려 놓지 않으면 관세에 직면할 것이라는 엄중한 경고를 했다고 보도되었다. 금요일(21일) 블룸버그 통신에 따르면 트럼프 대통령은 비공개 회의에서 제약사들에 임박한 관세에 대해 경고하며 해외 생산을 미국으로 서둘러 이전할 것을 촉구했다. 

트럼프, 거대 제약사에 경고 &#34;미국으로 생산 이전 안 하면 관세 부과&#34;

Biotech

Health Care

Technicals

Previews

Trading Ideas

General

머크 앤드 컴퍼니(NYSE:MRK)와 화이자(NYSE:PFE)는 화요일에 발표될 4분기 실적을 앞두고 투자자들의 관심을 끌기 위해 경쟁하고 있다. 이들 두 제약 대기업은 매우 다른 기술적 설정을 가지고 있어, 투자자들은 어떤 주식이 우위를 점할 것인지 궁금해하고 있다.

머크 vs 화이자: 4분기 실적에서 어떤 제약 거대기업이 우세할 것인가?

Dividends

AMGN

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

주식과 옵션을 볼 때 투자자들은 섹터 회전, 실적 강세, 다가오는 촉매제 등 여러 가지 전략을 사용한다. 가치 투자자들은 종종 배당주에서 강력한 실적 강세를 찾는다. 다우존스 산업평균지수에는 배당금을 지급하는 주식이 많이 포함되어 있으며, 꾸준히 배당금을 인상해 온 블루칩 기업들이 많다.

2025년 최대 6.8% 배당을 제공하는 고배당 주식 10선: 다우 지수의 주식

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

Merck &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) short percent of float has risen 26.56% since its last report. The company recently reported that it has 40.94 million shares sold short, which is 1.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Merck &amp; Co Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741808785_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merck &amp; Co has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Merck &amp; Co's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Merck &amp; Co's peer group average for short interest as a percentage of float is 4.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Merck & Co?

On Wednesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei&nbsp;(BIC/FTC/TAF) in trial&nbsp;MK-8591A-052) or antiretroviral therapy (bART) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in trial&nbsp;MK-8591A-051</a>.
In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44280630/merck-announces-positive-data-from-phase-3-trials-that-show-the-investigational-once-daily-oral-tw" rel="noreferrer noopener">objectives at Week 48</a>.
The company released the topline data from both studies <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600482/mercks-investigational-two-drug-regime-for-hiv-meets-primary-goal-in-two-late-stage-trials" rel="noreferrer noopener">in December 2024</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44252770/merck-injects-1-billion-to-expand-vaccine-production-in-us" rel="noreferrer noopener">Merck Injects $1 Billion To Expand Vaccine Production In US</a>
Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025.
<ul>
<li>In the trial MK-8591A-052, results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.5% of participants who switched to DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 0.6% on BIC/FTC/TAF.</li>
<li>At Week 48, 91.5% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 94.2% of participants who continued receiving BIC/FTC/TAF.</li>
</ul>
In the trial MK-8591A-051, results for the primary endpoint showed that 1.4% of participants who received DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 4.9% on bART.
<ul>
<li>At Week 48, 95.6% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 91.9% of participants who continued on bART.</li>
</ul>
Price Action: MRK stock is down 0.65% at $94.11 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44281844/arcos-dorados-q4-earnings-beat-estimates-stock-gains" target="_blank" rel="noreferrer noopener">Arcos Dorados Q4 Earnings: Sales Slip, EPS Beat, South Latin America Strength And More</a></li>
</ul>
Photo Courtesy of Merck

Large Cap

Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025

DOR/ISL demonstrated non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with virologically suppressed HIV-1
Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the presentation of positive results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in trial <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05630755&amp;esheet=54223136&amp;newsitemid=20250312706063&amp;lan=en-US&amp;anchor=MK-8591A-052&amp;index=1&amp;md5=d962319798a591d93c498e4e23a89f2f">MK-8591A-052</a>) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05631093%3Fterm%3Dislatravir%26page%3D2%26rank%3D20&amp;esheet=54223136&amp;newsitemid=20250312706063&amp;lan=en-US&amp;anchor=MK-8591A-051&amp;index=2&amp;md5=9f12d7e4233e638166ba99975cc400aa">MK-8591A-051</a>. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objectives at Week 48. The findings will be shared in late-breaking oral presentations at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco and were featured in a CROI press conference. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025.
In the double-blind trial MK-8591A-052 (Abstract #204A), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.5% of participants who switched to DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 0.6% on BIC/FTC/TAF (treatment difference 0.9%, 95% CI -1.9, 2.9). At Week 48, 91.5% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 94.2% of participants who continued receiving BIC/FTC/TAF (treatment difference -2.6%, 95% CI -7.1, 2.6; secondary endpoint).
In the open-label trial MK-8591A-051 (Abstract #204B), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.4% of participants who received DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 4.9% on bART (treatment difference -3.6%, 95% CI -7.8, -0.8. At Week 48, 95.6% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 91.9% of participants who continued on bART (treatment difference 3.7%, 95% CI -0.3, 8.9; secondary endpoint).
Across both trials, the safety profile of DOR/ISL was generally comparable to the comparator antiretroviral regimens, including BIC/FTC/TAF in MK-8591A-052. At Week 48, the mean percent change in total lymphocyte and CD4 counts were similar for DOR/ISL and comparator regimens. No treatment-emergent resistance to DOR or ISL was observed in either trial.

Merck Announces Data From Phase 3 Trials That Show The Investigational, Once-Daily, Oral, Two-Drug Regimen Of Doravirine/Islatravir Maintained HIV-1 Viral Suppression At Week 48

On Tuesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) opened a new $1 billion, 225,000-square-foot facility for vaccine manufacturing at its Durham, <a target="_blank" href="https://www.benzinga.com/news/large-cap" rel="noreferrer noopener">North Carolina, site</a>.
This expansion is a crucial component of the more than $12 billion Merck has invested in the U.S. since 2018. It&#8217;s focused on expanding domestic manufacturing and research and development capabilities. The company also aims to create new jobs in the U.S., with another $8-billion capital investment <a href="https://www.benzinga.com/pressreleases/25/03/b44242543/merck-unveils-new-facility-to-increase-vaccine-production-capacity" target="_blank" rel="noreferrer noopener">by 2028</a>.
Also Read: <a href="https://www.benzinga.com/25/03/44101319/pfizer-mulls-us-manufacturing-shift-amid-looming-tariff-threats-will-the-trump-administration-co-invest-asks-analyst" target="_blank" rel="noreferrer noopener">Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats</a>
During the fourth quarter, Merck reported a decline of 17% in sales of Gardasil to $1.55 billion. Gardasil is a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S. 
The decline is primarily due to lower demand in China, partially offset by higher demand in most international regions, <a href="https://www.benzinga.com/25/02/43461426/mercks-gardasil-vaccine-slowdown-in-china-bites-again-stock-falls-on-lower-than-expected-2025-outlook" target="_blank" rel="noreferrer noopener">particularly in Japan</a>.
Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 billion versus a consensus of $67.31 billion,&nbsp;including a negative impact of foreign exchange of approximately 2% at mid-January 2025 exchange rates.
The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year.
In February, at a press conference in&nbsp;Washington, D.C.,&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">manufacturing sites in&nbsp;the U.S</a>.
The company is currently negotiating with several states. The company's previous domestic capital expansion commitments from 2020 to&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility" rel="noreferrer noopener">2024 totaled&nbsp;$23 billion</a>.
In January, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>). 
After an inspection conducted last year, the agency flagged major concerns about Genzyme's processes <a href="https://www.benzinga.com/general/biotech/25/01/43142442/sanofi-genzyme-facility-fda-quality-lapses">for producing active pharmaceutical ingredients</a>.
Price Action: Merck stock is down 1.53% at $93.78 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44246625/dicks-sporting-beats-q4-earnings-stock-falls-amid-soft-outlook" target="_blank" rel="noreferrer noopener">Dick&#8217;s Sporting Beats On Q4 Earnings, Stock Falls Amid Soft Outlook</a></li>
</ul>
Image: Courtesy of Merck

Merck Injects $1 Billion To Expand Vaccine Production In US

Merck announces Opening Of New $1B 225,000-Square-Foot Facility Dedicated To Vaccine Manufacturing At Its Durham, North Carolina Site

Investors with a lot of money to spend have taken a bullish stance on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Merck &amp; Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 53% bullish and 38%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $141,686, and 10 are calls, for a total amount of $889,775.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $120.0 for Merck &amp; Co over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Merck &amp; Co options trades today is 3216.75 with a total volume of 4,215.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Merck &amp; Co's big money trades within a strike price range of $80.0 to $120.0 over the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741623348_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.99</td>
<td>$2.48</td>
<td>$3.05</td>
<td>$95.00</td>
<td>$457.5K</td>
<td>7.1K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.8</td>
<td>$0.79</td>
<td>$0.8</td>
<td>$105.00</td>
<td>$110.9K</td>
<td>8.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$9.5</td>
<td>$8.35</td>
<td>$9.5</td>
<td>$95.00</td>
<td>$75.9K</td>
<td>684</td>
<td>2</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.35</td>
<td>$7.25</td>
<td>$7.35</td>
<td>$90.00</td>
<td>$73.5K</td>
<td>8.9K</td>
<td>522</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.35</td>
<td>$7.2</td>
<td>$7.35</td>
<td>$90.00</td>
<td>$73.5K</td>
<td>8.9K</td>
<td>522</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Present Market Standing of Merck &amp; Co</h3>
<ul>
<li>With a volume of 5,153,380, the price of MRK is up 1.56% at $96.12. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 45 days.</li>
</ul>
<h3>Professional Analyst Ratings for Merck &amp; Co</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $110.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Hold, setting a price target of $105. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Merck &amp; Co, which currently sits at a price target of $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Merck & Co Unusual Options Activity For March 10

HC Wainwright has initiated coverage on ImmunityBio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>). The company's lead asset is Anktiva (nogapendekin alfa inbakicept-pmln) solution for intravesical use, approved by the Food and Drug Administration indicated with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or <a href="https://www.benzinga.com/general/biotech">without papillary tumors</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038889/immunitybio-stock-trading-higher-on-updates-from-bladder-cancer-trials-details" rel="noreferrer noopener">ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details</a>
HC Wainwright analyst Andres Y. Maldonado writes that Anktiva will follow a different market path than the two latest FDA-approved treatments for high-risk bladder cancer—Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda and Ferring Pharmaceutical's Adstiladrin—both of which have faced hurdles after launch.
Keytruda's adoption has been slow because urologists are hesitant to refer patients to oncologists and worry about its side effects. Adstiladrin, on the other hand, has struggled with supply issues, though Ferring says availability has recently improved.
HC Wainwright projects 2025 Anktiva revenue of $137.4 million, growing to $4.3 billion by 2034. The analyst has initiated with a Buy rating <a href="https://www.benzinga.com/quote/IBRX/analyst-ratings" target="_blank" rel="noreferrer noopener">and an $8 price target</a>.
In the fourth quarter, ImmunityBio reported <a href="https://www.benzinga.com/pressreleases/25/03/b44073991/immunitybio-reports-sales-momentum-unit-growth-since-permanent-j-code-issuance-j9028-in-january-20">product revenue of $7.21 million</a> and $14.2 million in the fiscal year 2024. The increase was driven by sales of ANKTIVA after FDA <a href="https://www.benzinga.com/general/biotech/24/04/38380405/fda-approves-immunitybios-bladder-cancer-drug-stock-rallies" target="_blank" rel="noreferrer noopener">approval in April 2024</a>.
Recently, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva and CAR-NK (PD-L1 t-haNK) for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or <a target="_blank" href="http://lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or metastatic pancreatic cancer." rel="noreferrer noopener">metastatic pancreatic cancer</a>.
While many are watching the competition between CG Oncology Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) cretostimogene and Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) TAR-200 in the NMIBC market, Anktiva stands out with a first-mover advantage in a market potentially worth over $5 billion, the analyst says.
&#8220;Ultimately, we believe ANKTIVA's profile coupled with ease of administration will weigh more heavily in treatment decisions than comparisons of complete response (CR) rates at various time points to unapproved products,&#8221; the analyst writes.
Price Action: IBRX stock is down 2.47% at $2.98 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44169989/federal-judge-halts-national-institutes-of-healths-grant-policy-overhaul-citing-legal-violations" target="_blank" rel="noreferrer noopener">Federal Judge Halts National Institutes of Health&#8217;s Grant Policy Overhaul Citing Legal Violations</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Initiation

Analyst Ratings

CGON

IBRX

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug

Investors with a lot of money to spend have taken a bullish stance on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Merck &amp; Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 16%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $108,276, and 9 are calls, for a total amount of $551,530.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $105.0 for Merck &amp; Co over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Merck &amp; Co's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Merck &amp; Co's whale trades within a strike price range from $80.0 to $105.0 in the last 30 days. 
<h3>Merck &amp; Co Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741114864_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$6.0</td>
<td>$5.65</td>
<td>$5.8</td>
<td>$90.00</td>
<td>$116.0K</td>
<td>10.2K</td>
<td>297</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$16.35</td>
<td>$16.15</td>
<td>$16.15</td>
<td>$80.00</td>
<td>$96.8K</td>
<td>2.9K</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.5</td>
<td>$90.00</td>
<td>$75.4K</td>
<td>10.2K</td>
<td>967</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.59</td>
<td>$1.46</td>
<td>$1.59</td>
<td>$95.00</td>
<td>$55.6K</td>
<td>5.8K</td>
<td>1.8K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.85</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$105.00</td>
<td>$55.2K</td>
<td>3.5K</td>
<td>119</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,710,730, the MRK's price is down by -0.3%, now at $92.87. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 51 days.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $108.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Market Perform rating on Merck &amp; Co, which currently sits at a price target of $96. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Merck &amp; Co, targeting a price of $112. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Merck &amp; Co, targeting a price of $115. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Merck &amp; Co, which currently sits at a price target of $115. 
&#x2A; Reflecting concerns, an analyst from Deutsche Bank lowers its rating to Hold with a new price target of $105.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Spotlight on Merck & Co: Analyzing the Surge in Options Activity

In light of potential tariff threats from President Donald Trump, Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla has suggested the possibility of shifting the company&#8217;s overseas manufacturing to its U.S. facilities.
What Happened: At the TD Cowen healthcare conference, Bourla indicated that Pfizer, which already boasts an extensive U.S. manufacturing network, could relocate production to its domestic plants to avoid any potential tariffs, reported Reuters on Monday.
His remarks come as the pharmaceutical industry braces for a possible 25% tariff on imported goods. &#8220;We&nbsp;have the capabilities here (in&nbsp;the U.S.) and the manufacturing&nbsp;sites are operating in good&nbsp;capacity right now. If something&nbsp;happens, we will try to&nbsp;mitigate it by transferring from&nbsp;manufacturing sites outside to the&nbsp;manufacturing sites here,&#8221; Bourla said.
Pfizer has 10 manufacturing facilities and two distribution centers in the United States. 
SEE ALSO:<a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets"> </a><a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">Trump&#8217;s Tariffs Threaten Canada, Mexico, China — And American Wallets</a>
Why It Matters: This development follows a&nbsp;<a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">warning</a>&nbsp;from Trump to pharmaceutical companies in February. During a confidential meeting, the President urged drug companies to expedite the transfer of their overseas production to the U.S. or face the possibility of tariffs.
Among the attendees of this meeting were the CEOs of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer, along with the head of the industry's largest lobbying group. The executives aimed to convince Trump to support measures targeting middlemen blamed for increasing out-of-pocket costs and to limit a law allowing the federal government to negotiate specific drug prices.
Though the Trump administration has hinted at possible exemptions to reciprocal tariffs for certain sectors, including pharmaceuticals, a final decision is yet to be made.
While many see reshoring as a potential solution to avoid tariffs, it may not be pragmatic. Independent healthcare analyst Joshua P. Cohen wrote in Forbes, &#8220;..this takes time and is logistically complex.&#8221; He stated that generic products might call for volume purchase guarantees, and a public-private partnership may be required to boost infrastructure and regulatory compliance. &#8220;Whether the Trump administration is prepared to co-invest in a long-term strategy remains to be seen,&#8221; says Cohen.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/general/social-media/25/03/44100560/reddit-co-founder-alexis-ohanian-joins-frank-mccourts-tiktok-bid-amid-competition-from-mrbeast-jesse-tinsley-and-reid-rasner">Reddit Co-Founder Alexis Ohanian Joins Frank McCourt&#8217;s TikTok Bid Amid Competition From MrBeast, Jesse Tinsley, And Reid Rasner</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst

Whales with a lot of money to spend have taken a noticeably bullish stance on Merck &amp; Co.
Looking at options history for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $69,435 and 7, calls, for a total amount of $1,203,898.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $85.0 to $95.0 for Merck &amp; Co during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 8273.17, with a total volume reaching 10,621.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $85.0 to $95.0, throughout the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740681954_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.75</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$90.00</td>
<td>$443.5K</td>
<td>12.3K</td>
<td>2.5K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$90.00</td>
<td>$351.0K</td>
<td>12.3K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.35</td>
<td>$2.15</td>
<td>$2.35</td>
<td>$90.00</td>
<td>$234.5K</td>
<td>10.7K</td>
<td>2.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.73</td>
<td>$1.7</td>
<td>$1.72</td>
<td>$95.00</td>
<td>$49.3K</td>
<td>6.3K</td>
<td>823</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$11.6</td>
<td>$11.25</td>
<td>$11.6</td>
<td>$85.00</td>
<td>$46.4K</td>
<td>307</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,348,312, the price of MRK is up by 0.87%, reaching $90.16.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $108.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Merck &amp; Co, maintaining a target price of $115. 
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Hold, setting a price target of $105. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Market Perform rating for Merck &amp; Co, targeting a price of $96. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Merck &amp; Co with a target price of $112. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on Merck &amp; Co, maintaining a target price of $115. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Decoding Merck & Co's Options Activity: What's the Big Picture?

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA&#xAE; (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 23, 2025.
The sBLA is based on data from the Phase 3 KEYNOTE-689 trial. Results from a pre-specified first interim analysis, which will be presented at an upcoming medical meeting, showed that in patients with resectable LA-HNSCC, the KEYTRUDA perioperative treatment regimen demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) compared to adjuvant radiotherapy (with or without cisplatin) alone. The study also showed a statistically significant improvement in major pathological response (mPR), a key secondary endpoint, for patients in the KEYTRUDA arm compared with adjuvant radiotherapy alone. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.

Government

Regulations

Merck's Keytruda Gains FDA Priority Review for Head and Neck Cancer Treatment

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs.
What Happened: During a confidential meeting, Trump alerted drug companies about the impending tariffs, urging them to hasten the transfer of their overseas production to the U.S., reported <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">Bloomberg</a> on Friday.
On Thursday, the CEO of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) David Ricks, CEO of Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Robert Davis, CEO OF Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Albert Bourla, and Stephen Ubl, head of the industry&#8217;s largest lobbying group met Trump at the White House. The executives aimed to persuade Trump to back efforts to limit a law permitting the federal government to negotiate specific drug prices and to support measures targeting middlemen whom the industry holds responsible for increasing out-of-pocket costs.
As per the Bloomberg report, Trump did not assure to advocate with Congress to alleviate a drug pricing program established under former President Joe Biden&#8216;s tenure, a relief that the pharmaceutical sector has been seeking.
Medicare officials confirmed on Friday that the next phase of the drug pricing negotiation program&nbsp;is due and would include Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster weight loss drugs, Ozempic and Wegovy. 
Meanwhile, Trump stated that Health and Human Services Secretary Robert F. Kennedy Jr. and his nominee for leading Medicare and Medicaid, Mehmet Oz, are working to reduce drug prices.
SEE ALSO: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43904842/dominos-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Domino&#8217;s Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Why It Matters: Last week, Trump proposed to <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">impose a 25% tariff </a>on pharmaceuticals imported to the U.S. This latest move by Trump is not surprising given his previous confrontations with the pharmaceutical industry. During his first term, he even accused them at one point of &#8220;getting away with murder&#8221; with their drug pricing. 
ING Bank estimates that the U.S. imported nearly 36% of the drugs in 2024 with Ireland, Germany, and Switzerland being the top importers. Meanwhile, data from the Atlantic Council shows that U.S. imports of Chinese drugs surged 485% between 2020-2022.&nbsp;Following Trump&#8217;s latest warning to drugmakers to shift production in the U.S., Chinese biotech shares have taken a hit during their Asian trading session today. Shares of WuXi Biologics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>) and Pharmaron Beijing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) witnessed significant declines. 
That being said, ING asserted that Trump&#8217;s call for expanding U.S. pharmaceutical manufacturing is justified, as a report from the Biden administration had indicated that capacity restrictions were the cause of drug shortages. However, a 2022 report by Washington University&nbsp;revealed that the capacity expansion would take between two to three years. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43901182/bernie-sanders-warns-if-elon-musk-can-fire-hundreds-of-thousands-of-federal-employees-imagine-what-hell-do-to-private-sector-workers">Bernie Sanders Warns: If Elon Musk Can Fire Hundreds Of Thousands Of Federal Employees, Imagine What He&#8217;ll Do To Private Sector Workers</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

Investors are scrambling to assess the potential fallout of yet <a href="https://www.benzinga.com/topic/tariffs">another tectonic trade decision</a>. 
What Happened: President Donald Trump plans to impose a 25% levy on <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">auto, semiconductor, and pharmaceutical imports</a>,
This move could have far-reaching consequences for <a href="https://www.benzinga.com/etfs">ETFs with heavy exposure to these sectors</a>, particularly those tracking automakers, chipmakers, and biotech firms.
Trump's protectionist stance triggered an immediate market response across the global markets. Asian stocks retreated after a five-day rally, with the MSCI Asia Pacific Index slipping, particularly affecting Japanese automakers like Toyota Motor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>).
Also Read: <a href="https://www.benzinga.com/news/global/25/02/43795579/warren-buffett-unfazed-by-trumps-tariff-threats-oracle-of-omaha-bets-on-mexico-beer">Warren Buffett Unfazed By Trump&#8217;s Tariff Threats: Oracle Of Omaha Bets On Mexico, Beer</a>
Automakers: The U.S. imported around 8 million passenger cars and light trucks last year, comprising 50% of total vehicle sales, according to a report by Wall Street Journal. A 25% tariff would increase vehicle prices, impact supply chains, and hurt companies dependent on overseas manufacturing. 
Here are a few ETFs likely to take a hit:
<ul>
<li>Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>): Fairly exposed to Toyota, Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and Ford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), this fund could face turbulence as trade tensions mount.</li>
</ul>
<ul>
<li>First Trust NASDAQ Global Auto Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARZ#NASDAQ">CARZ</a>): Tracks major global automakers, including BMW, Honda, and General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), which rely on imported parts. The ETF also has significant exposure to Toyota and Tesla and allocates 46% of its assets to overseas stocks. That places it in a precarious position amid escalating tariff situations.</li>
</ul>
Chips: Trump also declared that sectoral tariffs on semiconductors would start at "25% or higher", escalating further over time. This comes as the U.S. considers a 100% tariff on Taiwanese semiconductors, an industry heavily reliant on TSMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
<ul>
<li>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) – With Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) among its top holdings, this fund is exposed to volatility stemming from supply chain disruptions.</li>
</ul>
<ul>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) – Heavily weighted towards TSMC, Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), and Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), making it vulnerable to any tariff escalation.</li>
</ul>
Pharma: The pharmaceutical sector is also caught in the crosshairs, with Trump hinting at escalating tariffs beyond 25% over the year. This could upend drug pricing, R&amp;D costs, and supply chain dynamics for major biopharma companies.
<ul>
<li>iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>): Tracks major drugmakers like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), all of which could see higher costs.</li>
</ul>
<ul>
<li>SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>): While biotech firms often have global R&amp;D operations, increased tariffs could disrupt access to imported drug components.</li>
</ul>
Why It Matters: Trump has long voiced concerns over U.S. automotive exports being treated unfairly abroad. In his first term, he threatened a similar 25% car tariff but ultimately backed down.
For ETF investors, volatility is back on the table. Those holding funds exposed to autos, chips, and pharmaceuticals must brace for a bumpy ride. While Trump believes the move will bring manufacturing back home, the short-term pain could be severe.
The Wall Street Journal reported that U.S. companies may receive a phase-in period, with tariffs increasing over the course of the year.
What's Next: Markets will be watching closely as April 2 (when auto tariffs are expected to kick in) approaches. Any delays or modifications to the tariff plan could shift investor sentiment. 
For now, ETF traders should keep an eye on sectoral rotation, hedge exposure where necessary, and prepare for the potential impact of another round of trade wars.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/02/43794873/vanguard-overtakes-state-street-as-top-etf-provider-3-funds-in-focus">Vanguard Overtakes State Street As Top ETF Provider: 3 Funds In Focus</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

AAPL

AVGO

CARZ

DRIV

iShares Dow Jones US Pharmaceuticals Index Fund

INTC

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSLA

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports

Merck &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 29.60 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Merck &amp; Co Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739906112_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Merck &amp; Co has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Merck &amp; Co's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Merck &amp; Co's peer group average for short interest as a percentage of float is 4.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Merck & Co's Recent Short Interest

On Tuesday, the European Commission (EC) conditionally approved Merck&nbsp;&amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Welireg&nbsp;(belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43776493/welireg-belzutifan-receives-first-european-commission-approval-for-two-indications" rel="noreferrer noopener">as monotherapy for</a>:
<ul>
<li>Adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated, localized renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), and for whom localized procedures are unsuitable;</li>
<li>Adult patients with advanced clear cell RCC that progressed following two or more lines of therapy.</li>
</ul>
The approval of these two indications is based on results from the LITESPARK-004 and LITESPARK-005 trials, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43504863/analysts-defend-merck-amid-investor-concerns-over-weak-guidance" rel="noreferrer noopener">Analysts Defend Merck Amid Investor Concerns Over Weak Guidance</a>
This marks Welireg&#8217;s first approval in the European Union (EU). Welireg is now approved in over 30 countries for certain adult patients with previously treated advanced RCC and in more than 40 countries for adult patients with certain eligible VHL disease-associated tumors.
The conditional approval of Welireg will be valid for one year, subject to yearly renewal, pending additional clinical data from LITESPARK-004 and another ongoing Phase 2 trial of WELIREG in patients with certain VHL disease-associated tumors.
The FDA approved Welireg in <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Ffda-approves-mercks-hypoxia-inducible-factor-2-alpha-hif-2%25CE%25B1-inhibitor-welireg-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease%2F&amp;esheet=54207599&amp;newsitemid=20250218626672&amp;lan=en-US&amp;anchor=August+2021&amp;index=2&amp;md5=a3a0cf44dc5eb37aa0addd825cbd6482" rel="noreferrer noopener">August 2021</a> for adult patients with VHL disease who require therapy for associated RCC, CNS hemangioblastomas or pNET not requiring immediate surgery based on the results from LITESPARK-004.
Welireg was approved in the U.S. in&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Ffda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki%2F&amp;esheet=54207599&amp;newsitemid=20250218626672&amp;lan=en-US&amp;anchor=December+2023&amp;index=3&amp;md5=d079c702147c148646033ef950434190" rel="noreferrer noopener">December 2023</a> for adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-tyrosine kinase inhibitor based on the results from LITESPARK-005.
<h2 class="wp-block-heading">Merck Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Merck, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Merck &amp; Co, the 200-day moving average sits at $112.21, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $81.79. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: MRK stock is down 1.30% to $81.93 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Photo courtesy of Merck.

Eurozone

Europe Approves Merck's Cancer Drug For Two Indications

Merck Vaccine Case With Ties to HHS Secretary Kennedy Delayed; Merck Agrees To Halt Ongoing Trial Over HPV Vaccine In Los Angeles Superior Court; Merck And Plaintiff Suing Over Alleged Gardasil Vaccine Injuries Agree To Delay Trial Until September 2025 With New Jury

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Craig Hettenbach downgraded the rating for Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) from Overweight to Equal-Weight and raised the price target from $42 to $60. Hims &amp; Hers Health shares closed at $60.47 on Friday. <a href="https://www.benzinga.com/quote/HIMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst James Shin downgraded the rating for Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowered the price target from $128 to $105. Merck shares closed at $83.01 on Friday. <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Alex Zukin downgraded Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from Outperform to Peer Perform. Datadog shares closed at $131.01 on Friday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Gena Wang downgraded the rating for Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Overweight to Equal-Weight and lowered the price target from $111 to $45. Moderna shares closed at $32.99 on Friday. <a href="https://www.benzinga.com/quote/MRNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Paul Fremont downgraded Portland General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) from Buy to Neutral. Portland Gen Electric shares closed at $41.64 on Friday. <a href="https://www.benzinga.com/quote/POR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MRNA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="551" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-1024x551.png" alt="" class="wp-image-786944" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-1024x551.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153-768x413.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18085802/image-153.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Downgrades

Pre-Market Outlook

DDOG

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies raised Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) price target from $105 to $118. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Wynn Resorts shares closed at $88.82 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WYNN/analyst-ratings">view </a>this stock.</li>
<li>Keefe, Bruyette &amp; Woods increased the price target for Brighthouse Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) from $60 to $66. Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintained a Market Perform rating. Brighthouse Financial shares closed at $62.14 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BHF/analyst-ratings">view </a>this stock.</li>
<li>Morgan Stanley raised Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $42 to $60. Morgan Stanley analyst Craig Hettenbach downgraded the stock from Overweight to Equal-Weight. Hims &amp; Hers Health shares closed at $60.47 on Friday. See how other <a href="https://www.benzinga.com/quote/HIMS/analyst-ratings">analysts </a>view this stock.</li>
<li>Needham raised the price target for DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) from $60 to $65. Needham analyst Bernie McTernan maintained a Buy rating. DraftKings shares closed at $53.49 on Friday. <a href="https://www.benzinga.com/quote/DKNG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised the price target for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from $41 to $47. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Bath &amp; Body Works shares closed at $36.47 on Friday. <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Outlook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) price target from $30 to $3. HC Wainwright &amp; Co. analyst Douglas Tsao maintained a Buy rating. Outlook Therapeutics shares settled at $1.87 on Friday. <a href="https://www.benzinga.com/quote/OTLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $384 to $385. Canaccord Genuity analyst Whitney Ijem maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $256.45 on Friday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $255 to $305. Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained a Market Perform rating. Coinbase shares closed at $274.31 on Friday.  <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) from $155 to $150. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Dell shares settled at $114.38 on Friday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank cut Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) price target from $128 to $105. Deutsche Bank analyst James Shin downgraded the stock from Buy to Hold. Merck shares closed at $83.01 on Friday. <a href="https://www.benzinga.com/quote/mrk/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Price Target

ALNY

BBWI

Brighthouse Financial, Inc. - Common Stock

COIN

DELL

DKNG

OTLK

WYNN

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday

13 analysts have expressed a variety of opinions on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high estimate of $125.00, and a low estimate of $96.00. Observing a downward trend, the current average is 9.49% lower than the prior average price target of $124.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739883670_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Merck &amp; Co by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$105.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$112.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$96.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$106.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Daina Graybosch</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$119.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$121.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merck &amp; Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck &amp; Co compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Merck &amp; Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Merck &amp; Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MRK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merck &amp; Co analyst ratings.</a>
<h2>About Merck &amp; Co</h2>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Merck &amp; Co: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Merck &amp; Co's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.35%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Merck &amp; Co's net margin is impressive, surpassing industry averages. With a net margin of 18.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merck &amp; Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.17%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.74%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.86, Merck &amp; Co adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock

Deutsche Bank analyst James Shin downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowers the price target from $128 to $105.

Deutsche Bank Downgrades Merck & Co to Hold, Lowers Price Target to $105

Legal

Press Releases

ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

Merck Unveils New Facility to Increase Vaccine Production Capacity

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48

DEADLINE ALERT for ICLR, ESTC, FMC, MRK: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Merck & Co., Inc. Class Action: The Gross Law Firm Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK

Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Merck & Co., Inc. (MRK)

Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ESTC

ICLR

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Deutsche Bank

Guggenheim

B of A Securities

BMO Capital

Citigroup

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

도널드 트럼프 대통령은 제약 회사들에게 제조를 미국으로 되돌려 놓지 않으면 관세에 직면할 것이라는 엄중한 경고를 했다고 보도되었다.
무슨 일 있었나: 금요일(21일) <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">블룸버그</a> 통신에 따르면 트럼프 대통령은 비공개 회의에서 제약사들에 임박한 관세에 대해 경고하며 해외 생산을 미국으로 서둘러 이전할 것을 촉구했다.
목요일(20일)에는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) CEO인 데이비드 릭스(David Ricks), 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) CEO인 로버트 데이비스(Robert Davis), 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO인 앨버트 불라(Albert Bourla), 제약 산업 최대 로비 단체의 수장인 스티븐 유블(Stephen Ubl)이 백악관에서 트럼프와 만났다. 이들 경여진은 트럼프에게 연방 정부가 특정 의약품 가격을 협상할 수 있는 법안을 제한하는 노력을 지지해줄 것을 설득하고, 환자 부담 비용을 증가시키는 중개인에 대한 대책을 지지해줄 것을 요청했다.
블룸버그 보도에 따르면, 트럼프는 제약 업계가 요구해 온 조 바이든 전 대통령 재임 시절에 제정된 약가 프로그램 완화를 위해 의회를 지지하겠다고 약속하지는 않았다.
메디케어 관계자는 금요일에 약가 협상 프로그램의 다음 단계가 예정되어 있으며 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 블록버스터 체중 감량 약물인 오젬픽과 웨고비가 포함될 것이라고 확인했다.
한편, 트럼프 대통령은 로버트 F. 케네디 주니어 보건복지부 장관과 그의 메디케어 및 메디케이드 서비스센터장 지명자인 메멧 오즈(Mehmet Oz)가 약가 인하를 위해 노력하고 있다고 밝혔다.
왜 중요한가: 지난주 트럼프는 미국으로 수입되는 의약품에 <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">25%의 관세를 부과</a>할 것을 제안했다. 트럼프의 이러한 최근 움직임은 제약 업계와의 이전 대립을 고려할 때 놀라운 일이 아니다. 첫 임기 동안 그는 한때 제약업계가 약값으로 &#8216;살인&#8217;하고 있다고 비난하기도 했다.
ING 은행은 미국이 2024년에 약 36%의 의약품을 수입할 것으로 추정하며, 아일랜드, 독일, 스위스가 주요 수입국으로 꼽힌다. 한편, 대서양위원회의 데이터에 따르면 미국의 중국산 의약품 수입은 2020~2022년 사이에 485% 급증한 것으로 나타났다.
최근 트럼프 대통령이 제약회사에 미국 내 생산 전환을 경고한 이후, 중국 바이오테크 주가는 오늘 아시아 거래에서 큰 타격을 입었다. 우시 바이로직스(OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec우시 앱텍(OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>), 파마론 베이징(OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) 주가가 크게 하락했다.
그러나 ING는 바이든 행정부의 보고서에 따르면 용량 제한이 의약품 부족의 원인이라고 지적했기 때문에 미국 제약 제조를 확대하라는 트럼프의 요구가 정당하다고 주장했다. 하지만 워싱턴대학교의 2022년 보고서에 따르면 용량 확장에는 2~3년이 소요될 것이다.
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

트럼프, 거대 제약사에 경고 "미국으로 생산 이전 안 하면 관세 부과"

머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 화요일에 발표될 <a href="https://www.benzinga.com/earnings">4분기 실적</a>을 앞두고 투자자들의 관심을 끌기 위해 경쟁하고 있다.
이들 두 제약 대기업은 매우 다른 기술적 설정을 가지고 있어, 투자자들은 어떤 주식이 우위를 점할 것인지 궁금해하고 있다.
차트를 분석하고 각 회사가 실적 발표를 준비하는 과정에서 기술적 신호가 무엇을 말하고 있는지 살펴보겠다.
<h1 class="wp-block-heading">머 주식의 혼재된 신호: 단기적으로는 강세, 그러나 장기 저항선이 도사리고 있다</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-763045" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM.png" sizes="(max-width: 626px) 100vw, 626px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115322/Screenshot-2025-02-03-at-10.22.11-PM-300x235.png 300w" alt="" width="626" height="490" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다</a>
머크의 주식은 단기적으로 강한 모습을 보이고 있으며, 주가가 $98.90로 8일 및 20일 단순 이동 평균(SMA)인 각각 $97.81과 $98.64 위에 편안하게 자리 잡고 있다. 이러한 단기 매수 신호와 50.39로 중립적인 상대 강도 지수(RSI)는 실적 서프라이즈가 없다면 현재 추세가 지속될 것임을 시사한다.
그러나 머크 주식의 장기 추세를 살펴보면 이야기가 달라진다. 주가가 50일 SMA인 $99.64와 200일 SMA인 $114.28보다 낮아 앞으로 저항선에 직면할 수 있음을 나타낸다. 머크의 이동 평균 수렴 발산(MACD)이 -0.47로 나타나 근시일 내에 약세 모멘텀을 시사하며, 위험 요소가 추가된다.
반면, 애널리스트들은 머크에 대해 <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">$124의 목표주가</a>를 제시하며, 이는 20.25%의 상승 여력을 나타낸다. 이 긍정적인 전망이 단기 기술적 압박을 상쇄할 수 있어, 머크 주식은 실적 발표를 앞두고 혼재된 신호를 보이고 있다.
또한 읽어보세요: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr.와 빅파마: 보건부 장관 후보가 약물, 보험, 트럼프 행정명령에 대한 날카로운 질문에 답하다</a>
<h1 class="wp-block-heading">화이자 주식의 약세 하락세: 어려움을 극복할 수 있을까?</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-763046" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM.png" sizes="(max-width: 626px) 100vw, 626px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03115333/Screenshot-2025-02-03-at-10.21.55-PM-300x235.png 300w" alt="" width="626" height="490" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다</a>
대조적으로, 화이자 주식은 기술적으로 훨씬 약해 보인다. 주가가 5일, 20일, 50일 지수 이동 평균(EMA) 아래에 고정되어 있어 계속해서 매도 압력이 나타나고 있다. 화이자 주식이 $26.30에서 거래되고 있으며, 8일 SMA가 $26.51, 20일 SMA가 $26.56으로, 두 신호 모두 추가 하락 가능성을 시사한다.
화이자 주식의 50일 SMA인 $26.15가 약간의 지지를 제공하지만, 전체적으로 차트는 앞으로 더 많은 문제가 있음을 나타낸다. MACD 지표가 0.04로 나타나 약간의 강세 가능성만을 보여주고, RSI가 47.61로 주식에 대한 중립적인 감정을 강화한다. 단기적인 회복 가능성이 있지만, 화이자의 전반적인 추세는 머크보다 약해 보인다.
어려움에도 불구하고, 화이자의 애널리스트 <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">컨센서스 목표 주가</a>는 $36.74로, 13.80%의 상승 여력을 제공한다. 그러나 화이자 주식이 200일 SMA인 $27.87보다 상당히 낮이 거래되고 있는 만큼, 화이자는 힘든 길을 가야 함이 분명한다.
<h1 class="wp-block-heading">머크 vs 화이자: 누가 실적 대결에서 승리할 것인가?</h1>
실적에 관한 한, 머크의 탄탄한 애널리스트 전망과 강세의 단기 신호가 기술적 약세로 어려움을 겪고 있는 화이자보다 우위를 제공하는 것 같다.
두 주식 모두 리스크에 직면해 있지만, 머크의 상승 잠재력은 애널리스트들로부터 20%의 목표 주가 상향을 지원받아 안정성과 성장성을 원하는 투자자들에게 더 유망한 후보로 보이게 한다.
반면, 화이자는 여전히 더 높은 위험을 감내해야 하는 투자처로 남아 있지만, 기술적 장벽을 극복할 수 있다면 일부 상승 잠재력을 제공하기도 한다.
다음에 읽어보세요: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts">대형 제약사가 승리할 것인가? 골드만 삭스가 340B 및 메디케이드 변화에 대해 평가하다</a></li>
</ul>
사진: Merck: Zah108; Pfizer: Vadi Fuoco
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

주식과 옵션을 볼 때 투자자들은 섹터 회전, 실적 강세, 다가오는 촉매제 등 여러 가지 전략을 사용한다. 가치 투자자들은 종종 <a href="https://www.benzinga.com/topic/dividend-stocks">배당주에서</a> 강력한 실적 강세를 찾는다.
다우존스 산업평균지수에는 배당금을 지급하는 주식이 많이 포함되어 있으며, 꾸준히 배당금을 인상해 온 블루칩 기업들이 많다.
2025년을 맞이하기 앞서, 다우존스의 고수익 주식들을 살펴보겠다.
무슨 일이 있었나: 다우존스 산업평균지수는 2025년 대통령 선거 이후 여러 주식 지수가 상승세를 보인 가운데 12월에 45,000으로 사상 최고치를 기록했다.
12월 27일 기준으로, 다우존스 산업평균지수의 주식 18개가 연초 대비 상승했으며, 12개 구성 종목은 2024년 초와 비교하여 하락세를 보이고 있다.
투자자들은 다우존스 산업평균지수 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)를 통해 전체 다우존스 산업평균지수에 투자할 수 있지만, 지수의 30개 구성 종목 중 개별 주식을 선택할 수도 있다. 12월 27일 기준으로 ETF는 연초 대비 13.4% 상승했다.
인기 있는 전략 중 하나는 &#8220;다우의 개(Dogs of the Dow)&#8221; 주식에 주목하는 것이며, 이는 종종 배당금 지급률이 높은 하락세를 보이는 주식과 일치한다.
&#x2A;&#x2A; 다우의 개: 다우존스 지수를 추종하는 강아지라는 의미.
2025년을 시작하기 위해 가장 높은 수익률을 기록한 다우존스 산업평균지수의 주식들이 아래와 같이 정리되어 있다. 배당 수익률과 2024년 주식 실적이 나열되어 있다.
<ol>
<li>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.79% 수익률, 2024년 +5.9%</li>
<li>쉐브론 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.53% 수익률, 2024년 -3.5%</li>
<li>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.62% 수익률, 2024년 -8.8%</li>
<li>존슨앤드존슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.42% 수익률, 2024년 -7.5%</li>
<li>머크 앤드 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 3.25% 수익률, 2024년 -8.5%</li>
<li>코카콜라 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 3.11% 수익률, 2025년 +6.0%</li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): 3% 수익률, 2024년 +36.2%</li>
<li>시스코 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): 2.68% 수익률, 2024년 +18.0%</li>
<li>맥도날드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.41% 수익률, 2024년 -1.0%</li>
<li>프록터 앤드 갬블 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.37% 수익률, 2024년 +15.7%</li>
</ol>
2025년을 맞이하여 가장 높은 수익률을 기록한 주식 10개 중 7개가 2024년 초에도 상위 10개 주식 목록에 올라 있었으며, 머크, 맥도날드 및 프록터 앤드 갬블이 새롭게 다우의 개 주식 목록에 오른 것으로 나타났다.
또한 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%A7%80%EC%88%98%EC%97%90-%ED%95%A9%EB%A5%98-%EC%A7%80%EC%88%98%EC%97%90%EC%84%9C-%EC%96%B4%EB%96%A4-%EC%88%9C/" target="_blank" rel="noopener">엔비디아가 다우존스 산업평균지수에 포함된 것: 기술 대기업이 지수에서 차지하는 위치, 셔윈-윌리엄스 추가가 더 중요한 이유</a>
구성 변경이 수익률에 미치는 영향: 배당 투자자들은 그들이 익숙해진 높은 수익률의 주식들을 찾기 위해 다른 곳을 찾아야 할 것이다.
10.40%의 수익률을 제공하 월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)와 6.99%의 수익률을 주는 다우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)가 지수에서 교체되어 제외되었다.
2024년 새로운 다우존스 산업평균지수 구성 종목들은 높은 배당 수익률을 제공하지 않다. 셔윈-윌리엄스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)는 0.80%의 배당 수익률, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 0.03%의 배당 수익률, 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)은 배당금을 지급하지 않는다.
이는 다우존스 산업평균지수를 추적하는 ETF의 수익률이 낮아질 것을 의미하며, 과거 5년 동안 실적이 좋았던 주식으로 하락세를 보인 주식을 교체하여 더 강한 수익률을 추구하는 것이 목표이다.
최신 30개 다우존스 산업평균지수 구성 종목 중 28개 주식은 배당금을 지급하며, 아마존과 보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)은 예외이다.
다우존스 산업평균지수의 평균 배당 수익률은 약 2%이다.
알고 계셨나요?
<ul>
<li>의회가 대규모 투자를 하고 있습니다.  <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123024" target="_blank" rel="noreferrer noopener">2024년 선거를 앞두고 그들이 무엇을 사고 팔았는지 쉽게 확인할 수 있는 도구로 알아보세요</a></li>
</ul>
사진 출처: Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2024년 미국 주식 시장은 주요 지수가 주요 이정표를 돌파하며 새로운 기록을 세웠다. 올해 많은 주식이 큰 폭의 상승세를 보였지만, 애널리스트들은 여전히 일부 우량 주식의 수익률이 더 높아질 것으로 예상하고 있다.
<h3>2024년 다우존스 지수 실적</h3>
다우존스 산업평균 지수는 올해 8번의 1,000포인트 돌파 기록을 세웠다. 37,000선 부근에서 연초를 시작하여 12월 초에 45,000선을 돌파했다. 지수가 44,000에서 45,000까지 도달하는 데 단 7거래일밖에 걸리지 않았으며, 이는 역대 두 번째로 빠른 1,000포인트 돌파 기록이다.
그 후 지수는 1974년 이후 사상 최초로 최장 10일 연속 하락세를 기록하기도 했다. 이러한 10일간의 저조한 실적은 여러 가지 요인이 복합적으로 작용한 결과였따.
다우존스 지수에는 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) 같은 &#8216;매그니피센트 7&#8217; 종목이 모두 포함되지 않는다. 최근 다우존스 지수에 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 편입되었지만 주식의 저조한 실적 때문에 지수를 끌어내렸다.
다우존스 지수를 구성하는 유나이티드헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)는 이번 달 최고경영자 총격 사건 이후 큰 폭의 하락세를 보였다. 게다가 본질적으로 가격 가중 지수라는 역사적 장점은 오늘날 시장에서는 큰 단점이 되었다. 시가총액 가중 지수와 달리 가격 가중 지수는 고가 주식이 더 많은 비중을 차지하기 때문이다.
<h3>주요 다우존스 주식의 2025년 최고/최저 수익률 전망</h3>
애널리스트 추정치에 따르면 다우존스 지수 내 캐터필러(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), 유나이티드헬스, 셔윈 윌리엄스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)가 더 상승할 것으로 예상한다. 또한 아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), 쉐브론(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), 머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)에 대해서도 긍정적이다.
애널리스트들은 기업 실적에 따라 예측을 계속 업데이트하고 있으며, 새로운 실적 시즌이 시작되면 예상치는 변경될 수 있다.
선정 기준
<ul>
<li>다우존스 지수의 우량주 30개 종목</li>
</ul>
<ul>
<li>최고 및 최저 수익률은 <a href="https://pro.benzinga.com/dashboard">Benzinga Pro 데이터</a>의 12개월 평균 목표주가 기준</li>
</ul>
<figure class="block core-blockblock core-block table">
<table class="block core-block table" style="height: 393px;" width="908">
<tbody>
<tr>
<td>종목</td>
<td>시가총액         </td>
<td>목표주가 최고치 (달러)</td>
<td>목표주가 최저치 (달러)</td>
<td>컨센서스 목표주가 (달러)</td>
<td>상승/하락 여력 </td>
</tr>
<tr>
<td style="text-align: left;">캐터필러 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</td>
<td style="text-align: left;">176.73B</td>
<td style="text-align: left;">515</td>
<td style="text-align: left;">174</td>
<td style="text-align: left;">331.35</td>
<td style="text-align: left;">31.68%</td>
</tr>
<tr>
<td>유나이티드헬스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>460.26B</td>
<td>675</td>
<td>460</td>
<td>608.16</td>
<td>28.95%</td>
</tr>
<tr>
<td>셔윈 윌리엄스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)</td>
<td>86.71B</td>
<td>450</td>
<td>249</td>
<td>371.19</td>
<td>24.08%</td>
</tr>
<tr>
<td>아마존 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2,365.04B</td>
<td>290</td>
<td>197</td>
<td>247.05</td>
<td>23.82%</td>
</tr>
<tr>
<td>존슨앤드존슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>347.83B</td>
<td>215</td>
<td>40</td>
<td>168</td>
<td>22.41%</td>
</tr>
<tr>
<td>쉐브론 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</td>
<td>256.71B</td>
<td>212</td>
<td>160</td>
<td>179.36</td>
<td>21.42%</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>248.03B</td>
<td>155</td>
<td>104</td>
<td>126.24</td>
<td>20.76%</td>
</tr>
<tr>
<td>세일즈포스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>)</td>
<td>328.87B</td>
<td>450</td>
<td>236</td>
<td>378.52</td>
<td>20.60%</td>
</tr>
<tr>
<td>마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>3,246.07B</td>
<td>600</td>
<td>465</td>
<td>508</td>
<td>18.21%</td>
</tr>
<tr>
<td style="text-align: left;">비자 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td style="text-align: left;">622.63B</td>
<td style="text-align: left;">375</td>
<td style="text-align: left;">252</td>
<td style="text-align: left;">318.42</td>
<td style="text-align: left;">17.69%</td>
</tr>
</tbody>
</table>
</figure>
출처: Benzinga.com (2024년 12월 22일 데이터 기준)
<h3>캐터필러</h3>
<ul>
<li>캐터필러는 다우존스 구성 종목 중 31.68%의 가장 높은 상승 여력을 제시한다.</li>
<li><a href=""https://www.benzinga.com/quote/CAT/analyst-ratings"">Benzinga</a>에 따르면 캐터필러는 추적하는 28명의 애널리스트는 주당 331.35 달러의 컨센서스 목표주가를 제시했다.</li>
<li>트루이스트 증권의 제이미 쿡은 2024년 12월 19일 정부 이니셔티브와 민간 부문 프로젝트에 힘입어 인프라에 대한 상당한 투자가 캐터필러 장비 수요를 촉진할 것으로 예상하면서 목표주가를 주당 454달러에서 471달러로 상향 조정했다.</li>
<li>씨티그룹 애널리스트 카일 멩게스는 2024년 12월 9일 이 회사에 대한 &#8216;매수&#8217; 의견을 유지하고 목표주가를 435달러에서 460달러로 상향 조정했다.</li>
<li>12월 9일, JP모건의 애널리스트 타미 자카리아도 캐터필러에 대해 &#8216;매수&#8217; 의견을 유지하며 낙관적인 입장을 재확인했다. 동시에 캐터필러의 목표주가를 주당 500달러에서 515달러로 올렸.</li>
</ul>
<h3>유나이티드헬스 그룹</h3>
<ul>
<li>유나이티드헬스 그룹은 다우존스 구성 종목 중 두 번째로 높은 28.95%의 상승 잠재력을 가지고 있다.</li>
<li><a href=""https://www.benzinga.com/quote/UNH/analyst-ratings"">Benzinga</a>에 따르면 회사를 추적하는 26명의 애널리스트는 주당 331.35달러의 컨센서스 목표주가를 제시했다.</li>
<li>오펜하이머는 2024년 12월 6일에 목표주가를 주당 610달러에서 640달러로 올렸다. 목표주가 인상의 주된 이유는 오펜하이머 애널리스트가 재무 모델을 업데이트했기 때문이다. 이 업데이트는 유나이티드헬스가 8-K 신고서에서 공개한 공개 정보만을 기반으로 한 것으로 보인다.</li>
<li>스티븐스 앤 코는 2024년 12월 5일, 브라이언 톰슨 CEO의 치명적인 총격 사건으로 인해 투자자 컨퍼런스가 취소되기 전에 유나이티드헬스가 공유했던 2025년 가이던스 지표를 자세히 검토한 후 목표주가를 주당 605달러에서 675달러로 올렸다.</li>
<li>도이치은행은 이번 사건에 대한 투자자들의 포지션이 대부분 중립에서 긍정적이며, 3분기 전망에 비해 부정적인 수정을 예상하는 사람은 거의 없다고 판단하여 목표주가를 595달러에서 625달러로 상향 조정했다.</li>
</ul>
<h3>셔윈 윌리엄스 </h3>
<ul>
<li>셔윈-윌리엄스는 2025년까지 24.08%의 상승 잠재력을 가지고 있다.</li>
<li><a href=""https://www.benzinga.com/quote/SHW/analyst-ratings"">Benzinga</a>에 따르면 회사를 추적하는 25명의 애널리스트가 주당 371.19달러의 컨센서스 목표주가를 유지했다.</li>
<li>에버코어 ISI의 그렉 멜리치는 2024년 11월 7일 셔윈 윌리엄스의 목표주가를 주당 400달러에서 420달러로 올렸다.</li>
<li>RBC 캐피털의 아룬 비스와나탄은 2024년 10월 24일에 목표주가를 주당 455달러에서 446달러로 낮췄다. 비스와나탄은 3분기 실적이 투자자들의 기대에 미치지 못했다는 점을 인정하면서도, 시장 점유율 상승 가능성과 2025년 1월로 예정된 가격 인상의 긍정적인 영향을 강조했다.</li>
<li>씨티그룹은 2025년 상반기의 수요 부진이 금리 인하의 빠른 통과를 방해할 것으로 예상하면서 10월 24일에 목표주가를 430달러에서 420달러로 조정했다.</li>
</ul>
<h3>아마존</h3>
<ul>
<li>아마존의 2025년 상승률은 23.82%로 예상된다.</li>
<li><a href=""https://www.benzinga.com/quote/AMZN/analyst-ratings"">Benzinga</a>에 따르면 회사를 추적하는 39명의 애널리스트가 247.05달러 컨센서스 목표주가를 유지했다.</li>
<li>타이그리스 파이낸셜의 이반 페인세스는 2024년 12월 20일 아마존이 강력한 소매업 트렌드, 생성형 AI와 주문 처리 네트워크의 효과적인 활용, 전체 비즈니스에 걸친 AI의 전략적 통합에 힘입어 지속적인 성공을 거둘 수 있는 좋은 위치에 있다고 판단하여 목표주가를 245달러에서 290달러로 상향 조정했다.</li>
<li>번스타인은 운영 효율성과 사업 부문 전반의 지속적인 모멘텀에 따른 강력한 장기 성장에 대한 기대감으로 2024년 12월 18일에 목표주가를 주당 235달러에서 265달러로 상향 조정했다.</li>
<li>JP모건의 애널리스트 더글러스 앤머스는 아마존이 2025년 최고의 아이디어 종목이며, 앞으로 몇 달 동안의 AWS 성장에 대한 신뢰가 그 주요 이유라고 꼽았다. 그는 2024년 12월 18일에 목표주가를 250달러에서 280달러로 올렸다.</li>
</ul>
<h3>존슨앤드존슨</h3>
<ul>
<li>존슨앤드존슨은  2025년에 22.41%의 상승률을 기록할 것으로 예상되는 5위 종목이다.</li>
<li><a href=""https://www.benzinga.com/quote/JNJ/analyst-ratings"">Benzinga</a>에 따르면 회사를 추적하는 21명의 애널리스트는 168달러의 컨센서스 목표주가를 제시했다.</li>
<li>씨티그룹의 조앤 우엔쉬는 2024년 12월 11일 &#8216;매수&#8217; 의견을 유지하면서 존슨앤드존슨의 목표주가를 주당 185달러에서 175달러로 낮췄다.</li>
<li>뱅크오브아메리카 증권은 2024년 12월 10일에 &#8216;중립&#8217; 의견과 목표주가 166달러로 존슨앤존슨에 대한 커버리지를 재개시했다. 현재 존슨앤드존슨의 동종업계 대비 밸류에이션 프리미엄이 상승 잠재력을 제한할 수 있다고 지적한다. 그러나 애널리스트는 "상당히 흥미로운" 파이프라인을 인정하며 2025년에 탈크 관련 소송이 해결되면 도움이 될 것으로 예상한다. 이러한 분석은 11개의 미국 대형 제약 및 생명공학 기업에 대한 뱅크오브아메리카의 광범위한 커버리지 개시의 일환이었다.</li>
<li>울프 리서치의 애널리스트 알렉산드리아 해먼드는 2024년 11월 15일에 존슨앤존슨에 대해 &#8216;시장수익률 상회&#8217; 의견을 제시하고 주당 190달러의 목표주가를 설정했다.</li>
</ul>
<h3>쉐브론 코퍼레이션</h3>
<ul>
<li>쉐브론의 2025년 상승률은 21.42%로 예상된다.</li>
<li><a href=""https://www.benzinga.com/quote/CVX/analyst-ratings"">Benzinga</a>에 따르면 회사를 추적하는 24명의 애널리스트들은 179.36달러 컨센서스 목표주가를 제시했다.</li>
<li>파이퍼 샌들러의 애널리스트 라이언 토드는 2024년 12월 19일에 쉐브론의 목표주가를 주당 184달러에서 173달러로 낮추면서 &#8216;매수&#8217; 의견을 유지했다. 파이퍼 샌들러는 엑손모빌과 쉐브론 사이의 밸류에이션 격차는 헤스 코퍼레이션 인수 거래의 65% 이상이 실패할 확률을 의미한다고 말한다. 이 시나리오는 15%~25%의 상승 여력이 있는 반면, 거래가 성공할 경우 5%~10%의 하락 여력이 있다</li>
<li>이러한 거래 불확실성에도 불구하고 파이퍼 샌들러는 쉐브론이 2025년에 프로젝트 시작과 자본 지출 통제에 힘입어 강력한 포트폴리오 성과를 달성할 것으로 예상한다. 이로 인해 60~70억 달러의 잉여현금흐름이 크게 증가할 것으로 예상하고 있다.</li>
<li>웰스파고 애널리스트 로저 리드는 2024년 12월 9일에 쉐브론 목표주가를 171달러에서 188달러로 올렸다.</li>
<li>트루이스트 증권은 2024년 12월 6일에 &#8216;보유&#8217; 등급을 유지하면서 쉐브론의 목표주가를 155달러에서 160달러로 올렸다. 이 애널리스트는 충분한 로열티를 포함한 쉐브론의 상당한 재고를 강조하고 자본 효율성이 개선되어 내년에 현금 흐름이 개선될 것으로 예상한다.</li>
</ul>
<h3>머크</h3>
<ul>
<li>머크는 2025년까지 다우존스 지수에서 7번째로 높은 20.76%의 수익률을 기록할 것으로 예상된다.</li>
<li><a href=""https://www.benzinga.com/quote/MRK/analyst-ratings"">Benzinga</a>에 따르면 회사를 추적하는 27명의 애널리스트는 126.24달러 컨센서스 목표주가를 제시했다.</li>
<li>BMO 캐피털 마켓츠는 2024년 12월 20일에 목표주가를 136달러에서 105달러로 낮추면서 &#8216;시장수익률 상회&#8217;에서 &#8216;시장수익률&#8217;로 하향 조정했다. 이 하향 조정은 중국에서의 가다실(Gardasil) 프랜차이즈에 대한 우려와 키트루다(Keytruda)가 바이오시밀러 및 제네릭 의약품과의 경쟁 심화에 따른 잠재적 수익 격차를 반영한 것이다.</li>
<li>뱅크오브아메리카 증권의 팀 앤더슨은 2024년 12월 10일에 머크에 대해 &#8216;매수&#8217; 의견을 유지하면서 목표주가를 주당 127달러에서 121달러로 하향 조정하는 등 낙관적인 입장을 유지했다</li>
<li>트루이스트의 애널리스트 로빈 카르나우스카스는 2024년 11월 7일 머크에 대한 &#8216;매수&#8217; 의견을 재확인했지만 목표주가는 주당 132달러에서 130달러로 낮췄다.</li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Equities

Long Ideas

GOOG

GOOGL

MSFT

2025년에 최고의 수익률 낼 수 있는 우량주 7종목

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)의 주가가 목요일에 소폭 반등세를 보이고 있지만 여전히 약세에서 벗어나지 못한 형국이다.
주가가 결국 95.00달러 정도 수준에 도달하면 주가가 반전되어 상승할 가능성이 높다. 차트에서 볼 수 있듯이 이는 11월 말에 일어난 일이다. 이러한 이유로 우리 기술 분석 팀은 이를 <a href="https://kr.benzinga.com/?s=%EC%98%A4%EB%8A%98%EC%9D%98+%EC%A3%BC%EC%8B%9D+" target="_blank" rel="noopener">오늘의 주식</a>으로 선정했다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-700197" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" alt="Merck" width="1024" height="557" /></figure>
머크에서 많은 뉴스가 나왔다.
고급 암 유전자 검사 제공업체인 퍼스널리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)가 머크로부터 5천만 달러의 지분 투자를 받았다고 발표했다. 거래가 마무리되면 머크는 퍼스널리스의 16.5%를 소유하게 된다.
또한 머크은 <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">수익성 높은 비만 시장에 진입</a>한다고 발표했다. 중국 바이오텍 기업 한소제약(Hansoh Pharmaceutical Group Company Limited)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)로부터 GLP-1 수용체 경구 투여제의 라이센스를 획득했다.
머크의 차트는 몇 가지 간단하지만 가치 있는 기술적 분석 교훈을 제공한다. 저항선이었던 가격 수준이 지지선으로 변환될 수 있다. 또한 지지선까지 주가가 하락하면 반등하는 경향이 있다.
추가 읽기: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">테바 제약, 위장 관련 질환 2상 후보 데이터 발표</a>
119.40달러는 2023년 5월 저항선이었다. 당시 매도한 일부 투자자들은 가격이 곧바로 하락하자 좋은 결정을 내렸다고 생각했다.
하지만 2024년 1월 저항선을 돌파하고 주가가 상승했다. 이때 일부 매도자들은 실수를 했다고 생각하고 매도한 가격에 주식을 다시 사기로 결정했다.
그래서 주가가 2024년 3월에 다시 119.40달러 수준으로 하락하자 이들은 매수 주문을 넣었다. 이 주문의 대량 집중이 이전의 저항선 가격에서 지지선으로 형성되었다.
유사한 행동이 111.00달러 수준에서도 발생했다. 2023년 8월 저항선이었으나 2024년 8월에는 지지선이 되었다.
2022년 7월에는 95.00달러 수준이 저항선이었다. 지난달 지지선으로 전환되었고, 머크가 다시 도달하면 지지선이 될 수 있다.
이 차트에서 볼 수 있듯이, 주가가 지지선에 도달한 후 상승하는 경우도 있다. 이는 지지선을 형성한 일부 매수자들이 더 높은 가격에 팔려고 할 때 발생한다. 다른 사람이 더 높은 가격을 지불할 의사가 있다면, 매도자들은 그쪽으로 간다.
결과적으로 그들은 지불할 의사가 있는 가격을 인상한다. 다른 이들도 이를 보고 동일한 행동을 취한다. 이는 주가를 상승시키는 눈덩이 효과를 유발할 수 있으며, 머크에서도 곧 발생할 수 있다.
주가 움직임: 머크의 주식은 목요일 미국 동부 시간 오후 2시 10분에 1.16% 상승한 99.44달러에 거래되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">비트코인, 연준 회의 후 102,000달러 이상 반등; 미국 GDP 3.1% 증가, 실업 수당 청구 감소, 국채 수익률 정점 – 오늘의 주요 뉴스</a></li>
</ul>
이미지 출처: Merck.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Merck & Co

뉴스

에 대한 최신 뉴스 Merck & Co (NYSE:MRK) 주식

월요일, 2월 24, 2025

월요일, 2월 03, 2025

수요일, 1월 01, 2025

목요일, 12월 26, 2024

월요일, 12월 23, 2024

목요일, 12월 19, 2024

금요일, 10월 11, 2024

화요일, 9월 03, 2024

일요일, 8월 04, 2024

일요일, 7월 07, 2024

화요일, 7월 02, 2024

금요일, 4월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌